載入中
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
一般交易時段
US$16.915
+US$0.125 · +0.74%
盤中時間採用ET。市場資料可能有所延遲。
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
日內區間
目前US$16.915
52週區間
目前US$16.915
盤中時間採用ET。市場資料可能有所延遲。
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
日內區間
目前US$16.915
52週區間
目前US$16.915
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 85.8萬 USD | 63.6萬 USD | — | — | — |
| 銷貨成本 | 9.2萬 USD | 3950.7萬 USD | 15萬 USD | — | 10.9萬 USD |
| 毛利 | 76.6萬 USD | −3887.1萬 USD | −15萬 USD | — | −10.9萬 USD |
| 研究與開發 | 1959.7萬 USD | 4150.7萬 USD | 5354.4萬 USD | 4068.9萬 USD | 2690.9萬 USD |
| 銷售、一般及管理費用 | 1432.5萬 USD | 1832.5萬 USD | 2538.8萬 USD | 2719.5萬 USD | 1873.9萬 USD |
| 營業費用 | 2883萬 USD | 2162.5萬 USD | 7893.2萬 USD | 6788.4萬 USD | 4564.8萬 USD |
| 利息收入 | 218.9萬 USD | 421.6萬 USD | 614.7萬 USD | 196.3萬 USD | 5.4萬 USD |
| 利息支出 | — | — | — | — | 1萬 USD |
| 折舊和攤銷 | 9.2萬 USD | 13.1萬 USD | 15萬 USD | 16.7萬 USD | 10.9萬 USD |
| 營業利益 | −2806.4萬 USD | −6049.6萬 USD | −7893.2萬 USD | −6788.4萬 USD | −4564.8萬 USD |
| 淨利 | −897.8萬 USD | −5777.5萬 USD | −7456.4萬 USD | −6665.4萬 USD | −4701.3萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年2月6日 | 1:8 | — | — |
已生效 2026年2月6日
1:8
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI226.03萬0.00%2.3兆 USD0.03%US$381.2-0.10%
Vanguard Extended Market ETFVXF54.48萬0.00%954億 USD0.05%US$233-0.22%
iShares Micro-Cap ETFIWC20.42萬0.02%13.17億 USD0.60%US$181.36-0.17%
Dimensional - US Small Cap ETFDFAS11.36萬0.00%338.04億 USD0.31%US$78.29+0.15%
U.S. Micro Cap Portfolio ETFDFMC10.03萬0.00%75.44億 USD0.43%US$57.86+0.28%
Avantis U.S. Small Cap Equity ETFAVSC2.66萬—30.79億 USD0.25%US$70.20+0.33%
U.S. Vector Equity Portfolio ETF Class SharesDXUV1.22萬0.00%61.96億 USD0.26%US$68.26-0.09%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR1.16萬0.00%455.76億 USD0.17%US$84.32-0.13%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASU.S. Micro Cap Portfolio ETFDFMCAvantis U.S. Small Cap Equity ETFAVSCU.S. Vector Equity Portfolio ETF Class SharesDXUVU.S. Core Equity 1 Portfolio ETF Class SharesDCORAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
